Eikon's meaty $517.8 million series B comes on the heels of a $148 million series A round last May.
Eikon Therapeutics, Inc., a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has named Alfred “Freddie” Bowie, Jr, PhD, to the newly created position of Chief Financial Officer. In this role, Dr. Bowie will have broad responsibility for finance, operational functions, and business development.